Knock-out and transgenic mouse models of tauopathies
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Tauopathies, characterized by the dysfunction and aggregation of the microtubule-associated protein tau (MAPT), represent some of the most devastating neurodegenerative disorders afflicting the elderly, including Alzheimer's disease and progressive supranuclear palsy. Here we review the range of Mapt knock-out and MAPT transgenic mouse models which have proven successful at providing insights into the molecular mechanisms of neurodegenerative disease. In this overview we highlight several themes, including the insights such models provide into the cellular and molecular mechanisms of tauopathy, the direct relationship between neuropathology and behaviour, and the use of mouse models to help provide a platform for testing novel therapies. Mouse models have helped clarify the relationship between pathological forms of tau, cell death, and the emergence of disease, as well as the interaction between tau and other disease-associated molecules, such as the Aβ peptide. Finally, we discuss potential future MAPT genomic DNA models to investigate the importance of alternative splicing of the MAPT locus and its role in sporadic tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · cited 16×
“[PubMed: 14032480] Lambourne SL, Sellers LA, Bush TG, Choudhury SK, Emson PC, Suh YH, Wilkinson LS. Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau…”
BackgroundInfluentialLee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“In contrast, PSP patients and FTDP-17 patients with mutations in exon 10 tend to display neurofibrillary tangles consisting only of straight tau filaments (Lee et al., 2001).”
ResultSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“Similarly, the TAPP line, generated by crossing P301L tau mice with Aβproducing Tg2576 mice, demonstrates the likelihood of a link between Aβ and tau pathology, with the former exerting an influence on the latter (Lewis et al., 2001).”
BackgroundMutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 1×
“At least 30 different mutations in the MAPT locus have been identified in families suffering from FTDP-17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998 and Brandt et al., 2005; D'Souza and Schellenberg, 2005; Goedert and Jakes, 2005 for reviews).”
BackgroundTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374 · cited 1×
“At least 30 different mutations in the MAPT locus have been identified in families suffering from FTDP-17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998 and Brandt et al., 2005; D'Souza and Schellenberg, 2005; Goedert and Jakes, 2005 for reviews).”
BackgroundLewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 1×
“The first of that kind was the JNPL3 line, with 4R/0N tau (four-repeat, no aminoterminal inserts) under the control of the mouse prion promoter (Arendash et al., 2004; Lewis et al., 2000; Lin et al., 2003a,b, 2005).”
BackgroundPaired Helical Filaments in Electron Microscopy of Alzheimer's Disease
KIDD, M. (1963) · Nature · doi:10.1038/197192b0 · Cited by 1,012 · cited 1×
“For instance, in AD, neurofibrillary tangles consist of both twisted hyper-phosphorylated tau filaments (paired helical filaments) and of single non-periodical tau filaments (straight filaments) (Kidd, 1963).”
BackgroundTau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781 · cited 1×
“Moreover, a number of sporadic tauopathies, in particular PSP and CBD, have been linked to haplotypespecific sequence variations in MAPT (Baker et al., 1999; Conrad et al., 1997; Di Maria et al., 2000; Houlden et al., 2001; Pittman et al., 2005).”
BackgroundHanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737 · cited 1×
“Along with cyclin-dependent kinase 5 (Cdk5), GSK-3 is one of the main kinases thought to be involved in the aberrant phosphorylation of tau in neurodegenerative disease (e.g. Hanger et al., 1992; Mandelkow et al., 1992).”
BackgroundHyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 2×
“The chronic administration of lithium in mice overexpressing wild-type or mutant human MAPT has been shown to reduce hyperphosphorylation of tau (Noble et al., 2005; Perez et al., 2003) and in some cases even to reverse tau pathology and behavioural abnormalities observed in aged mice (Engel et…”
BackgroundRamsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · cited 2×
“The Tg4510 line expresses the P301L MAPT mutation (4R/0N tau) under the control of a tet-inducible CaMKII promoter (Ramsden et al., 2005; Santacruz et al., 2005; Spires et al., 2006).”
BackgroundDickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · cited 6×
“Another such candidate is the C-terminus of the Hsp70-interacting protein (CHIP) which is a crucial catalyst for chaperone-mediated protein ubiquitination and degradation of abnormally phosphorylated and folded tau proteins (Dickey et al., 2007b).”
BackgroundInfluentialSchneider, A., Biernat, J., von Bergen, M., Mandelkow, E., & Mandelkow, E.-M. (1999) · Biochemistry · doi:10.1021/bi981874p · Cited by 564
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564 · cited 1×
“The first MAPT transgenic models used complementary DNA (cDNA) vectors to overexpress various human wild-type tau isoforms in the mouse brain (Brion et al., 1999; Gotz et al., 1995; Higuchi et al., 2002; Ishihara et al., 1999, 2001; Probst et al., 2000).”
BackgroundInhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice
Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., & Vitek, M. P. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1179 · Cited by 527
Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau
Mandelkow, E.-M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J., Vandenheede, J. R., & Mandelkow, E. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81496-9 · Cited by 515 · cited 1×
“Along with cyclin-dependent kinase 5 (Cdk5), GSK-3 is one of the main kinases thought to be involved in the aberrant phosphorylation of tau in neurodegenerative disease (e.g. Hanger et al., 1992; Mandelkow et al., 1992).”
BackgroundCell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms
Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511 · cited 3×
“Thus, Andorfer and colleagues used electron microscopy in their human tau (htau) mice, and reported that the presence of tau filaments did not correlate with the death of individual cells (Andorfer et al., 2005).”
BackgroundMethodTau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495 · cited 2×
“G272V was one of the earliest mutations to be used for MAPT transgenic models (Gotz et al., 2001b; Lim et al., 2001), and on its own, seems to result in hyperphosphorylated tau not only in neurons, but also in oligodendrocytes (Gotz et al., 2001b).”
BackgroundProteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice
David, D. C., Hauptmann, S., Scherping, I., Schuessel, K., Keil, U., Rizzu, P., Ravid, R., Dröse, S., Brandt, U., Müller, W. E., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500356200 · Cited by 447 · cited 2×
“In particular, mitochondrial complex V proteins were reduced, just as they were in post-mortem brains of four FTDP-17 patients with the same mutation (David et al., 2005).”
BackgroundMutations causing neurodegenerative tauopathies
Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438 · cited 2×
“2 promoter NFTs in cortex, spinal cord; mitochondrial dysfunction Small increase in exploratory behaviour; accelerated extinction; weight loss; intact spatial working memory, but impaired spatial reference memory Gotz et al. (2001a), Pennanen et al.”
BackgroundCorticobasal degeneration and progressive supranuclear palsy share a common tau haplotype
Houlden, H., Baker, M., Morris, H. R., MacDonald, N., Pickering–Brown, S., Adamson, J., Lees, A. J., Rossor, M. N., Quinn, N. P., Kertesz, A., et al. (2001) · Neurology · doi:10.1212/wnl.56.12.1702 · Cited by 409 · cited 1×
“Moreover, a number of sporadic tauopathies, in particular PSP and CBD, have been linked to haplotypespecific sequence variations in MAPT (Baker et al., 1999; Conrad et al., 1997; Di Maria et al., 2000; Houlden et al., 2001; Pittman et al., 2005).”
BackgroundSpires, T. L., Orne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., & Hyman, B. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050840 · Cited by 401
The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340 · cited 2×
“Furthermore, it appears that the negative effect of GSK-3 on tau phosphorylation can be modulated by Cdk5 which was shown to act as an inhibitor of GSK-3 in a Cdk5 mouse model (Plattner et al., 2006).”
BackgroundTau domains, phosphorylation, and interactions with microtubules
Mandelkow, E.-M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., & Mandelkow, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00025-a · Cited by 308
GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila
Mudher, A., Shepherd, D., Newman, T. A., Mildren, P., Jukes, J. P., Squire, A., Mears, A., Berg, S., MacKay, D., Asuni, A. A., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001483 · Cited by 265 · cited 3×
“[PubMed: 14643079] Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila.”
BackgroundResultInfluentialEngel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223 · cited 2×
“…(Cdk5) Lithium inhibition of GSK-3, responsible for aberrant phosphorylation of tau, could be shown to reduce and sometimes reverse tau pathology Engel et al. (2006), Mudher et al. (2004), Nakashima et al. (2005), Noble et al. (2005), Perez et al. (2003), Plattner et al. (2006) CHIP/Hsp90…”
BackgroundArendash, G. W., Lewis, J., Leighty, R. E., McGowan, E., Cracchiolo, J. R., Hutton, M., & Garcia, M. F. (2004) · Brain Research · doi:10.1016/j.brainres.2004.02.081 · Cited by 127
Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice
Ikeda, M., Kawarai, T., Kawarabayashi, T., Matsubara, E., Murakami, T., Sasaki, A., Tomidokoro, Y., Ikarashi, Y., Kuribara, H., Ishiguro, K., et al. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62274-2 · Cited by 120 · cited 1×
“All of the lines are based on 4R/2N tau which, however, was put under the control of different promoters (Egashira et al., 2005; Ikeda et al., 2005; Tatebayashi et al., 2002; Zhang et al., 2004).”
Background
Research works printed but not linked: 61
- Allen, 2002, Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein, J. Neurosci., 22, 9340, 10.1523/JNEUROSCI.22-21-09340.2002 · DOI · Paper page
- Andreadis, 1992, Structure and novel exons of the human tau gene, Biochemistry, 31, 10626, 10.1021/bi00158a027 · DOI · Paper page
- Bellucci, 2004, Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein, Am. J. Pathol., 165, 1643, 10.1016/S0002-9440(10)63421-9 · DOI · Paper page
- Boekhoorn, 2006, Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy, J. Neurosci., 26, 3514, 10.1523/JNEUROSCI.5425-05.2006 · DOI · Paper page
- Brandt, 2005, Tau alteration and neuronal degeneration in tauopathies: mechanisms and models, Biochim. Biophys. Acta, 1739, 331, 10.1016/j.bbadis.2004.06.018 · DOI · Paper page
- Brion, 1999, Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease, Am. J. Pathol., 154, 255, 10.1016/S0002-9440(10)65272-8 · DOI · Paper page
- Caffrey, 2006, Haplotype-specific expression of exon 10 at the human MAPT locus, Hum. Mol. Genet., 15, 3529, 10.1093/hmg/ddl429 · DOI · Paper page
- Chambers, 1999, Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease, Ann. Neurol., 46, 325, 10.1002/1531-8249(199909)46:3<325::AID-ANA8>3.0.CO;2-V · doi:10.1002/1531-8249(199909)46:3<325::aid-ana8>3.0.co;2-v
- Conrad, 1997, Genetic evidence for the involvement of tau in progressive supranuclear palsy, Ann. Neurol., 41, 277, 10.1002/ana.410410222 · DOI · Paper page
- Delacourte, 1998, Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation, Ann. Neurol., 43, 193, 10.1002/ana.410430209 · DOI · Paper page
- Dickey, 2007, Brain CHIP: removing the culprits in neurodegenerative disease, Trends Mol. Med., 13, 32, 10.1016/j.molmed.2006.11.003 · DOI
- Di Maria, 2000, Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy, Ann. Neurol., 47, 374, 10.1002/1531-8249(200003)47:3<374::AID-ANA15>3.0.CO;2-8 · doi:10.1002/1531-8249(200003)47:3<374::aid-ana15>3.0.co;2-8
- D'Souza, 2005, Regulation of tau isoform expression and dementia, Biochim. Biophys. Acta, 1739, 104, 10.1016/j.bbadis.2004.08.009 · DOI
- Duff, 2000, Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes, Neurobiol. Dis., 7, 87, 10.1006/nbdi.1999.0279 · DOI · Paper page
- Egashira, 2005, Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice, Brain Res., 1059, 7, 10.1016/j.brainres.2005.08.004 · DOI
- Fung, 2006, Association of tau haplotype-tagging polymorphisms with Parkinson's disease in diverse ethnic Parkinson's disease cohorts, Neurodegener. Dis., 3, 327, 10.1159/000097301 · DOI
- Geschwind, 2003, Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?, Neuron, 40, 457, 10.1016/S0896-6273(03)00681-0 · DOI
- Gotz, 1995, Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform, EMBO J., 14, 1304, 10.1002/j.1460-2075.1995.tb07116.x · DOI · Paper page
- Gotz, 2001, Oligodendroglial tau filament formation in transgenic mice expressing G272V tau, Eur. J. Neurosci., 13, 2131, 10.1046/j.0953-816x.2001.01604.x · DOI · Paper page
- Harada, 1994, Altered microtubule organization in small-calibre axons of mice lacking tau protein, Nature, 369, 488, 10.1038/369488a0 · DOI · Paper page
- Healy, 2004, Tau gene and Parkinson's disease: a case-control study and meta-analysis, J. Neurol. Neurosurg. Psychiatry, 75, 962, 10.1136/jnnp.2003.026203 · DOI · Paper page
- Hernandez, 2004, Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35 Implications for Alzheimer's disease, J. Biol. Chem., 279, 3801, 10.1074/jbc.M311512200 · DOI · Paper page
- Higuchi, 2002, Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration, Neuron, 35, 433, 10.1016/S0896-6273(02)00789-4 · DOI · Paper page
- Higuchi, 2005, Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies, J. Neurosci., 25, 9434, 10.1523/JNEUROSCI.2691-05.2005 · DOI · Paper page
- Ikegami, 2000, Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice, Neurosci. Lett., 279, 129, 10.1016/S0304-3940(99)00964-7 · DOI · Paper page
- Ishihara, 2001, Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice, Am. J. Pathol., 158, 555, 10.1016/S0002-9440(10)63997-1 · DOI · Paper page
- Karnik, 2006, Non-fluent progressive aphasia, depression, and OCD in a woman with progressive supranuclear palsy: neuroanatomical and neuropathological correlations, Neurocase, 12, 332, 10.1080/13554790601125957 · DOI
- Katsuse, 2006, Neurofibrillary tangle-related synaptic alterations of spinal motor neurons of P301L tau transgenic mice, Neurosci. Lett., 409, 95, 10.1016/j.neulet.2006.09.021 · DOI
- Lambourne, 2005, Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities, Mol. Cell. Biol., 25, 278, 10.1128/MCB.25.1.278-293.2005 · DOI · Paper page
- Laws, 2007, Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease, Mol. Psychiatry., 12, 510, 10.1038/sj.mp.4001935 · DOI
- Lim, 2001, FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain, Mol. Cell. Neurosci., 18, 702, 10.1006/mcne.2001.1051 · DOI · Paper page
- Lin, 2003, Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation, Am. J. Pathol., 162, 213, 10.1016/S0002-9440(10)63812-6 · DOI
- Lin, 2003, Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau, J. Neurocytol., 32, 1091, 10.1023/B:NEUR.0000021904.61387.95 · DOI
- Lin, 2005, Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau, J. Neurocytol., 34, 397, 10.1007/s11068-006-8726-0 · DOI
- Morozov, 2003, Using conditional mutagenesis to study the brain, Biol. Psychiatry, 54, 1125, 10.1016/S0006-3223(03)00467-0 · DOI
- Mukherjee, 2007, Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease, BMC Genet., 8, 3, 10.1186/1471-2156-8-3 · DOI · Paper page
- Murakami, 2006, Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation, Am. J. Pathol., 169, 1365, 10.2353/ajpath.2006.051250 · DOI
- Myers, 2005, The H1c Haplotype at the MAPT locus is associated with Alzheimer's Disease, Hum. Mol. Genet., 14, 2399, 10.1093/hmg/ddi241 · DOI · Paper page
- Myers, 2007, The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts, Neurobiol. Dis., 25, 561, 10.1016/j.nbd.2006.10.018 · DOI · Paper page
- Nakashima, 2005, Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies, Acta Neuropathol. (Berl.), 110, 547, 10.1007/s00401-005-1087-4 · DOI
- Pastor, 2004, Novel haplotypes in 17q21 are associated with progressive supranuclear palsy, Ann. Neurol., 56, 249, 10.1002/ana.20178 · DOI
- Pennanen, 2004, Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice, Neurobiol. Dis., 15, 500, 10.1016/j.nbd.2003.11.020 · DOI · Paper page
- Pennanen, 2006, Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice, Genes Brain Behav., 5, 369, 10.1111/j.1601-183X.2005.00165.x · DOI · Paper page
- Perez, 2003, Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model, J. Alzheimers Dis., 5, 301, 10.3233/JAD-2003-5405 · DOI · Paper page
- Pittman, 2005, Linkage disequilibrium fine-mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration, J. Med. Genet., 42, 837, 10.1136/jmg.2005.031377 · DOI · Paper page
- Pittman, 2004, The structure of the tau haplotype in controls and in progressive supranuclear palsy, Hum. Mol. Genet., 13, 1267, 10.1093/hmg/ddh138 · DOI · Paper page
- Probst, 2000, Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein, Acta Neuropathol. (Berl.), 99, 469, 10.1007/s004010051148 · DOI · Paper page
- Schindowski, 2006, Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits, Am. J. Pathol., 169, 599, 10.2353/ajpath.2006.060002 · DOI · Paper page
- Shahani, 2002, Functions and malfunctions of the tau proteins, Cell. Mol. Life Sci., 59, 1668, 10.1007/PL00012495 · DOI · Paper page
- Skipper, 2004, Linkage disequilibrium and association of MAPT H1 in Parkinson disease, Am. J. Hum. Genet., 75, 669, 10.1086/424492 · DOI · Paper page
- Takanashi, 2002, Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration, Brain Res. Mol. Brain Res., 104, 210, 10.1016/S0169-328X(02)00382-0 · DOI
- Takei, 2000, Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes, J. Cell Biol., 150, 989, 10.1083/jcb.150.5.989 · DOI · Paper page
- Tanemura, 2001, Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau, Neurobiol Dis., 8, 1036, 10.1006/nbdi.2001.0439 · DOI · Paper page
- Tanemura, 2002, Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau, J. Neurosci., 22, 133, 10.1523/JNEUROSCI.22-01-00133.2002 · DOI · Paper page
- Taniguchi, 2005, Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation, FEBS Lett., 579, 5704, 10.1016/j.febslet.2005.09.047 · DOI · Paper page
- Tatebayashi, 2002, Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau, Proc. Natl. Acad. Sci. U.S.A., 99, 13896, 10.1073/pnas.202205599 · DOI · Paper page
- Terwel, 2005, Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice, J. Biol. Chem., 280, 3963, 10.1074/jbc.M409876200 · DOI · Paper page
- Yao, 2005, Preserved synaptic vesicle recycling in hippocampal neurons in a mouse Alzheimer's disease model, Biochem. Biophys. Res. Commun., 330, 34, 10.1016/j.bbrc.2005.02.121 · DOI
- Zehr, 2004, Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice, Neurobiol. Dis., 15, 553, 10.1016/j.nbd.2003.12.011 · DOI · Paper page
- Zhang, 2004, Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy, J. Neurosci., 24, 4657, 10.1523/JNEUROSCI.0797-04.2004 · DOI · Paper page
- Zhang, 2005, The tau gene haplotype h1 confers a susceptibility to Parkinson's disease, Eur. Neurol., 53, 15, 10.1159/000082956 · DOI
Cited by
Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
“Tauopathy can be modeled by transgenic overexpression of different human familial FTDP mutations (Denk and Wade-Martins, 2009), and common features of these mutant mouse strains include neurofibrillary tangles that increase in number with age and progressive neurodegeneration (Lewis et al.”
BackgroundSydow, A., Van der Jeugd, A., Zheng, F., Ahmed, T., Balschun, D., Petrova, O., Drexler, D., Zhou, L., Rune, G., Mandelkow, E., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5245-10.2011 · Cited by 302
Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model
Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272
Takeuchi, H., Iba, M., Inoue, H., Higuchi, M., Takao, K., Tsukita, K., Karatsu, Y., Iwamoto, Y., Miyakawa, T., Suhara, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021050 · Cited by 247
“Several tauopathy mouse models have contributed to the novel pathophysiological findings of tauopathies, including behavioral abnormalities [14].”
Background
Metadata
- Authors
- Denk, F., & Wade-Martins, R.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 30
- Issue
- 1
- Pages
- 1-13
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2053330721
- Cited by
- 120
- References
- 33
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.